Drug Database
HE

hepatitis-B vaccine

✓ Approved

China National Pharmaceutical · RARB · Vaccine

What is hepatitis-B vaccine?

hepatitis-B vaccine is a vaccine developed by China National Pharmaceutical. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyChina National Pharmaceutical
Drug ClassVaccine, Large Molecules
Molecular TargetRARB
RouteInjectable (Others)
StatusApproved

Mechanism of Action

Molecular Targets

hepatitis-B vaccine acts on 1 molecular target:

RARBretinoic acid receptor beta (RRB2, HAP)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

hepatitis-B vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsHepatitis B✓ Approved

Related Research Articles

PubMedThe American journal of the medical sciences2026-08-30

The Evolving Burden of Hepatitis B and C: Past Trends and Future Projections from the Global Burden of Disease Study 2021.

Chen Yue Y, Mao He-Hui HH, Zhang Ming-Jing MJ, Zhang Jin-Yan JY et al.

Hepatitis B and C continue to pose significant challenges to global public health, and this study is aimed at evaluating their burden. Leveraging data from the Global Burden of Disease 2021, we analyzed age-standardized mortality rates (ASMRs) and age-standardized disability-adjusted life year rates (ASDRs) for hepatitis B and C from 1990 to 2021 using Joinpoint regression, age-period-cohort models, and decomposition analysis. Bayesian age-period-cohort models were applied to project future trends up to 2036. Additionally, we assessed the burden attributable to modifiable risk factors and its association with socioeconomic indicators. From 1990 to 2021, the global ASMR for hepatitis B declined from 12.19 to 7.57 per 100,000, and the ASMR for hepatitis C decreased from 8.18 to 6.10 per 100,000. Despite these decreases, the absolute numbers of deaths and DALYs continued to increase, mainly driven by population growth and aging. In 2021, males carried a disproportionately higher burden of hepatitis B and C compared to females. Moreover, countries with low socioeconomic development faced a greater burden. Notably, high alcohol consumption accounted for 16.20% of hepatitis B DALYs, while drug use was responsible for 49.49% of hepatitis C DALYs. By 2036, ASMRs are projected to decline further to 5.90 per 100,000 for hepatitis B and 5.23 per 100,000 for hepatitis C. Although ASMRs and ASDRs have declined, the global burden of hepatitis B and C remains considerable. Continued efforts in vaccination, antiviral treatment, and control of key risk factors are crucial, especially in populations with a high burden.

PubMedJapanese journal of infectious diseases2026-08-30

Evaluation of the Virucidal Activity of Chlorine Dioxide against Hepatitis B Virus.

Chen Ming M, Pereira Caroline Donzeli CD, Watashi Koichi K, Shibata Takashi T et al.

Hepatitis B virus (HBV) remains a major global public health concern, with numerous nosocomial and occupational outbreaks reported. Preventing indirect HBV transmission through effective disinfection is crucial. This study evaluated the virucidal activity of chlorine dioxide (ClO₂) against HBV and compared it with sodium hypochlorite (NaClO). Pretreatment of HBV with ClO₂ at 10, 100, and 250 ppm (mg/L) for 1 min reduced hepatitis B surface antigen (HBsAg) release to 65.5%, 21.9%, and 7.0%; hepatitis B core (HBc)-positive cells to 59.1%, 27.0%, and 6.6%; intracellular HBV RNA to 71.5%, 31.6%, and 3.0%; and extracellular HBV DNA to 82.2%, 42.6%, and 14.1%, respectively. At identical concentrations, NaClO produced smaller reductions. In the presence of organic matter, no significant reduction in ClO₂ activity against HBV was observed. ClO₂ demonstrated approximately 2.2-fold greater anti-HBV potency than NaClO with and without bovine serum albumin and sheep erythrocytes. Neutralizer, cell-permissiveness, and ultrafiltration controls supported direct viral inactivation. These findings indicate that ClO₂ showed stronger in vitro anti-HBV activity than NaClO within the tested concentration range and conditions.

PubMedKidney international reports2026-08-30

Hepatitis B Virus-Associated Cryoglobulinemic Glomerulonephritis Misdiagnosed as Lupus Nephritis: the Value of Clinicopathologic Integration.

Nguyen Thoi The TT, Dang Nghia Thanh NT, Hoang Uyen U, Nghiem Dung Trung DT et al.

PubMedThe Journal of veterinary medical science2026-08-30

Remarkable similarity between domestic cat hepatitis B virus strains identified in stray cats and outbreak-associated strains from a cat shelter in Okinawa, Japan.

Houri Yuika Y YY, Kato Nanami X NX, Adachi Yukinobu Y, Kawano Miki X MX et al.

We recently identified a domestic cat hepatitis B virus (DCHBV) outbreak at a cat shelter in Okinawa, Japan. Viral genome sequencing showed that this particular strain was highly conserved and distinct from previously reported Japanese strains, suggesting that a single strain had spread within the shelter. However, the origin of this strain remained unclear. DCHBV strains were also identified in two stray cats in central Okinawa. The outbreak strain shared 99.4-99.8% and 99.5-99.8% nucleotide identity with the strain from stray cat #1 and #2, respectively, indicating a close genetic relationship among all DCHBV strains identified in Okinawa. Our findings highlight the importance of screening stray cats for DCHBV before admission to shelters to help prevent outbreaks.

PubMedAnalytical biochemistry2026-08-30

Validation of SARS-CoV-2 neutralization assay using VSV-based pseudovirus system.

Artarini Anita A, Tan Marselina Irasonia MI, Giri-Rachman Ernawati Arifin EA, Natalia Dessy D et al.

The gold standard for SARS-CoV-2 neutralization assays involves wild-type virus, which requires Biosafety Level 3 (BSL-3) containment. To improve safety and accessibility, pseudovirus-based neutralization assays utilizing non-replicating particles like Vesicular Stomatitis Virus (VSV) expressing the SARS-CoV-2 spike protein can be conducted under BSL-2 conditions. This study aimed to perform the analytical validation of a VSV-based pseudovirus system for SARS-CoV-2 using recombinant monoclonal antibody. Pseudo-VSV carrying SARS-CoV-2 Spike proteins were produced using LentiX-293T cells. The assay system was optimized for Multiplicity of Infection (MOI) and assessed for specificity, limit of quantification (LOQ), linearity, accuracy, and precision using the neutralizing mAb BD-604. The system was optimized at an MOI of 0.25. The assay proved highly specific, as mAb BD-604 showed clear neutralizing activity while mAb 1A9 did not. The limit of quantification (LOQ) was determined to be 125 ng of mAb BD-604, with a linear range of 125 - 1000 ng. The relative accuracy remained within the 80-120% range, and the precision (%CV) ranged from 1.92% to 13.57%. Additionally, the system successfully characterized variant-specific neutralization, revealing that BD-604 was effective against the Wuhan, Delta, and Omicron BA.1/BA.2 strains but lacked activity against the Omicron XBB.1.5 variant. This validated pseudo-VSV based SARS-CoV-2 neutralization assay is a valuable bioassay for evaluating neutralizing antibody potency against various SARS-CoV-2 strains in a BSL-2 environment, thus making it useful for vaccine and therapeutic development.

PubMedJournal of agromedicine2026-08-30

Skin Cancer in Rural Workers in Brazil: Influence of Ultraviolet Radiation, Skin Color and Regional Factors.

Moraes Rufini de Souza Lucas L, Minette Luciano José LJ, Schettino Stanley S, de Almeida Guimarães Marcelo M et al.

This study analyzed the incidence of skin cancer among rural workers in Brazil, considering the influence of ultraviolet (UV) radiation, skin color, and regional factors. Data from the National Cancer Institute (2008-2022) on skin cancer were used, using historical series of the Ultraviolet Index (UVI) obtained via satellite and cross-referenced with population information obtained from the Brazilian Institute of Geography and Statistics. Between 2008 and 2022, Brazil recorded 81,378 cases of skin cancer related to rural workers, with an average incidence rate of 318.23 cases per 100,000. The UVI is high in the North and North-East regions of the country, but the highest rate of skin cancer occurs in the South, where 73% of the population is white and the UVI is lower. Correlation and regression analyses revealed that the UVI, the proportion of white people, and the percentage of rural workers significantly influence the skin cancer rate. These results show that approximately 28% of a rural worker's risk of developing skin cancer may be related to the interaction between biological and environmental factors and that prevention and sun protection strategies should take into account demographic and regional variability.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about hepatitis-B vaccine